SHR 4640Alternative Names: SHR-4640
Latest Information Update: 12 Jan 2017
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Small molecules; Uricosurics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Gout
Most Recent Events
- 01 Sep 2016 Phase-I clinical trials in Gout (In volunteers) in Australia (PO) (NCT03015948)
- 01 Jul 2016 Jiangsu HengRui Medicine Co initiates a phase I trial in Healthy volunteers in China (PO) (NCT02890966)
- 23 Jun 2016 Phase-I clinical trials in Gout (In volunteers) in China (PO) (NCT02815839)